PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
11.24%
ROE below 50% of AGEN's 22.76%. Michael Burry would look for signs of deteriorating business fundamentals.
-6452.67%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
25.02%
ROCE below 50% of AGEN's 136.99%. Michael Burry would question the viability of the firm’s strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.